The quality of platelet concentrates related to corrected count increment: linking in vitro to in vivo

Saris, Anno; Kreuger, Aukje L.; Brinke, Anja ten; Kerkhoffs, J.L.; Middelburg, Rutger A.; Zwaginga, Jaap Jan; Meer, Pieter F. van der

doi:10.1111/trf.14868

Cited by 13 publications

(20 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…63 Recently, van der Meer and colleagues investigated correlations between in vitro assays and the corrected-count increment (CCI) at 1 hour in hemato-oncology patients. 64 The CCI enables the evaluation of the increase in circulating platelets after a transfusion, corrected for the body surface and the dose. It is indicative of a good recirculation of the transfused platelets.…”

Section: Correlation To In Vivo Datamentioning

confidence: 99%

What about Platelet Function in Platelet Concentrates?

Prudent

2020

Hamostaseologie

View full text Add to dashboard Cite

The characterization of platelet concentrates (PCs) in transfusion medicine has been performed with different analytical methods and platelet lesions (from biochemistry to cell biology) have been documented. In routine quality assessment and validation of manufacturing processes of PCs for transfusion purposes, only basic parameters are monitored and the platelet functions are not included. However, PCs undergo several manipulations during the processing and the basic parameters do not provide sensitive analyses to properly picture out the impact of the blood component preparation and storage on platelets. To improve the transfusion supply chain and the platelet functionalities, additional parameters should be used. The present short review will focus on the different techniques to monitor ex vivo platelet lesions from phenotype characterization to advanced omic analyses. Then, the opportunities to use these methods in quality control, process validation, development, and research will be discussed. Functional markers should be considered because they would be an advantage for the future developments in transfusion medicine.

show abstract

Section: Correlation To In Vivo Datamentioning

confidence: 99%

What about Platelet Function in Platelet Concentrates?

Prudent

2020

Hamostaseologie

View full text Add to dashboard Cite

show abstract

“…Overall, an enhanced presence of platelet activation markers has to be considered an indicator of the development of apoptotic mechanisms during platelet storage, predicting reduced platelet recoveries and survival . However, if these changes only represent natural apoptosis, they should not necessarily indicate a critical reduction in platelet functions.…”

Section: In Vitro Testsmentioning

confidence: 99%

“…Maximal amplitude parameters in the previous settings seem slightly deteriorated versus standard plasma platelets, though clotting time could be shortened. A combined score of quality including TEG parameter has shown a moderate correlation with the corrected count increment at 1 hour . More recently, TEG has been applied to cold‐stored and cryopreserved concentrates.…”

Section: In Vitro Testsmentioning

confidence: 99%

“…Autologous transfusions of radiolabeled platelets in healthy research subjects was an early approach to investigate recovery and survival of platelet transfusions . This approach has provided valuable data on the quality of different platelet products but not on the effects of the platelets on bleeding. Clinical studies on the association of platelet recoveries and corrections of bleeding times were performed in the past, though this approach is no longer considered acceptable.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Platelet in vitro assays: their correspondence with their in vivo hemostatic potential

Escolar

McCullough

2019

Transfusion

View full text Add to dashboard Cite

Developments during the past few years have resulted in multiple kinds of platelet products for transfusion. This involves different collection methods, containers, preservative solutions, modifications of storage temperatures and durations, and additional treatments such as pathogen reduction. Much experience has been obtained testing these processes in vitro to seek indications of in vivo effectiveness. Availability of an in vitro method that correlated with in vivo effectiveness would be extremely valuable for these different kinds of platelet products and as more innovation in platelet preparation occurs in the future. This report reviews the methods for in vitro platelet testing with a view to their in vivo implications and whether such testing could be helpful in projecting the clinical effectiveness of different platelet products. ABBREVIATIONS: ADP = adenosine diphosphate; ATP = adenosine triphosphate; GP = glycoprotein; PAR = proteaseactivated receptor; PASs = platelet additive solutions; PCs = platelet concentrates; PRT = pathogen reduction technology; TEG = thromboelastography; TRAP = thrombin-activated receptor peptide; VWF = von Willebrand factor. From the

show abstract

“…2 Multiple causes for PLT refractoriness have been defined, including nonimmune causes (sepsis, disseminated intravascular coagulation, medication, splenomegaly), immune causes such as ABO incompatibility or when platelet-reactive IgG antibodies specifically target the transfused platelets, and characteristics of the transfusion product. 1,3,4 Nonimmune causes are involved in the majority of cases, 5 but up to 20% of cases are attributed to platelet-reactive antibodies alone. 6,7 The presence of platelet-reactive allo-antibodies is known as allo-immunization, and these antibodies can be directed toward polymorphic HLAs, or, less frequently, polymorphic human platelet antigens (HPA) and platelet glycoproteins.…”

Section: Introductionmentioning

confidence: 99%

The association and functional relevance of genetic variation in low‐to‐medium‐affinity Fc‐gamma receptors with clinical platelet transfusion refractoriness

Nagelkerke

Porcelijn

Geissler

et al. 2020

Journal of Thrombosis and Haemostasis

View full text Add to dashboard Cite

Background: Inadequate responses to platelet transfusions (i.e., platelet transfusion refractoriness [PLT refractoriness]) are a serious problem. Multiple factors contribute to low yields upon platelet transfusion, among which are platelet-reactive alloantibodies. Platelet-reactive allo-antibodies occur in up to 30% of patients receiving multiple transfusions, and presumably lead to rapid destruction of the transfused platelets via receptors for IgG, the Fc-gamma receptors (FcγRs). Genetic variation in FcγRs is associated with susceptibility to immune thrombocytopenia, in which autoantibodies against platelets cause thrombocytopenia. Objectives:We hypothesized that genetic variation in FcγRs may also influence PLT refractoriness in allo-immunized patients and could help in identifying the patients at risk. How to cite this article: Nagelkerke SQ, Porcelijn L, Geissler J, et al. The association and functional relevance of genetic variation in low-to-medium-affinity Fc-gamma receptors with clinical platelet transfusion refractoriness.

show abstract

The quality of platelet concentrates related to corrected count increment: linking in vitro to in vivo

Cited by 13 publications

References 31 publications

What about Platelet Function in Platelet Concentrates?

What about Platelet Function in Platelet Concentrates?

Platelet in vitro assays: their correspondence with their in vivo hemostatic potential

The association and functional relevance of genetic variation in low‐to‐medium‐affinity Fc‐gamma receptors with clinical platelet transfusion refractoriness

Contact Info

Product

Resources

About